Q&A // LY3437943
Retatrutide: Common Questions
Direct answers to the questions most frequently asked about retatrutide, sourced from the published literature.
Is retatrutide better than tirzepatide?
Phase 2 head-to-head data do not yet exist. Indirect comparison: retatrutide 12 mg produced a mean -24.2% body-weight change at 48 weeks in its Phase 2 obesity trial [1]. Tirzepatide achieved approximately -22.5% at the highest dose in its Phase 3 obesity trials. A dedicated active-comparator Phase 3 trial (NCT06662383) comparing the two compounds head-to-head is ongoing; results have not been published [8]. A 2024 comparative review of seven GLP-1 receptor agonists and polyagonists positioned retatrutide among the highest-efficacy agents [7].
How to switch from tirzepatide to retatrutide?
Retatrutide is not approved; it cannot be prescribed. In trial protocols, prior incretin use was often a washout criterion or subject to dose-adjustment oversight by clinicians. Switching between incretin-class agents affects GI tolerability and blood-sugar response and requires clinical supervision. This site does not provide switching guidance — that question requires a treating clinician who can monitor the transition in real time.
Is retatrutide the same as Ozempic?
No. Ozempic is the brand name for semaglutide, a GLP-1 receptor agonist that is FDA-approved. Retatrutide is an investigational GIP/GLP-1/glucagon triple agonist, not approved anywhere. The two compounds share the GLP-1 receptor as a target, but retatrutide additionally targets GIP and glucagon receptors. They are different molecules made by different companies, with different approval statuses, different mechanisms, and different clinical profiles.
Is retatrutide better than semaglutide?
Phase 2 figures favor retatrutide on weight loss: -24.2% at 48 weeks at 12 mg [1] versus semaglutide's approximately -14-17% in its obesity Phase 3 trials. A 2024 comparative review of seven GLP-1-class agents and polyagonists positioned retatrutide as one of the highest-efficacy agents [7], and a 2026 network meta-analysis ranked retatrutide highest for weight and HbA1c reduction among the glucagon receptor agonist class [11]. However, semaglutide is FDA-approved with extensive long-term and outcomes trial data; retatrutide has Phase 2 data only and no long-term outcomes results yet. See the dedicated is retatrutide better than semaglutide page for the full comparison.
How does retatrutide compare to a dual GLP-1/GIP agonist in Phase 3 studies?
Phase 3 head-to-head data comparing retatrutide to a dual GIP/GLP-1 agonist have not been published. In Phase 2, retatrutide at 12 mg over 48 weeks produced a mean -24.2% body-weight change versus -2.1% placebo [1]. The dedicated active-comparator Phase 3 trial (NCT06662383) pitting retatrutide directly against tirzepatide is ongoing but unpublished [8]. Indirect comparisons from systematic reviews suggest retatrutide is among the highest-efficacy agents in the class [11][14].
How does retatrutide compare to tirzepatide in terms of weight loss?
Indirect comparison only, from separate trials: retatrutide 12 mg achieved a mean -24.2% weight change at 48 weeks in Phase 2 [1]. Tirzepatide (a dual GIP/GLP-1 agonist) achieved approximately -22.5% in its highest-dose Phase 3 arm. A 2026 network meta-analysis ranked retatrutide highest for weight reduction among the glucagon receptor agonist drug class [11]. Direct comparison awaits the results of NCT06662383 [8]. See the full retatrutide vs tirzepatide analysis for the detailed breakdown.
What does retatrutide do?
Retatrutide activates three hormone receptors simultaneously — GLP-1R (appetite suppression, insulin secretion), GIPR (insulin amplification, fat-tissue effects), and GCGR (increased energy expenditure, liver-fat metabolism). In Phase 2 trials, this combination produced weight loss, HbA1c reduction, and substantial liver-fat clearance. A 2025 review characterized the ~24% weight-loss result as a step-change versus prior incretin therapies [6].
How does retatrutide work?
Retatrutide binds GLP-1R, GIPR, and GCGR simultaneously. GLP-1 receptor activation suppresses appetite and stimulates glucose-dependent insulin release. GIP receptor activation amplifies the insulinotropic effect and influences fat-cell metabolism. Glucagon receptor activation increases energy expenditure and hepatic lipid mobilization. Cryo-EM structures resolved this triple engagement at near-atomic resolution; relative potency is ~8.9× at GIPR, ~0.4× at GLP-1R, and ~0.3× at GCGR compared to the endogenous hormones [3]. The downstream signal in all three receptors is cAMP/PKA.
How to reconstitute retatrutide?
No reconstitution standard exists for retatrutide outside clinical trials — it is not approved and has no commercial formulation. In trials, retatrutide was supplied as a pre-formulated sterile solution administered by injection. Research-labeled lyophilized (freeze-dried) material outside trials has no published preparation protocol and carries unverified identity and purity risks. This site does not provide reconstitution instructions for non-clinical materials.
Is retatrutide FDA approved?
No. As of mid-2026, retatrutide is not approved by the FDA or any regulatory agency. It is in Phase 3 clinical trials (the TRIUMPH program) in obesity, type 2 diabetes, cardiovascular outcomes, and chronic kidney disease. A 2024 Clinical Diabetes profile explicitly described retatrutide as an investigational first-in-class triple agonist [9]. Approval, if the Phase 3 trials succeed, would require NDA submission and FDA review — no timeline has been confirmed.
When will retatrutide be available?
Retatrutide is available only through clinical trials as of mid-2026. Phase 3 results are pending. No regulatory submission date has been confirmed. Eli Lilly's Phase 3 program timelines are consistent with potential NDA submission in 2026-2027 if trial results support it — but this depends on outcomes data that have not yet been published. No commercial availability date can be confirmed.
How to take retatrutide?
In clinical trials, retatrutide was administered as a subcutaneous injection once weekly, with a stepwise dose escalation to the target level. Retatrutide is investigational and not approved; it cannot be prescribed. The administration protocol used in trials is not transferable to unmonitored self-use of gray-market material, which carries identity, purity, and sterility risks not present in clinical-trial settings.
How long does retatrutide take to work?
In the Phase 2 obesity trial, weight loss was measurable from early weeks and accumulated progressively, reaching a mean -24.2% at 48 weeks for the 12 mg group [1]. A 2025 review noted the weight loss trajectory as a step-change versus prior incretin agents [6]. The half-life of approximately 6 days means steady-state plasma levels are reached after approximately four to five weeks of once-weekly dosing [4]. Community reports describe early appetite changes — particularly food-noise reduction — within the first few weeks.
How much retatrutide per week?
In Phase 2 trials, doses of 1, 4, 8, and 12 mg once weekly were studied. The highest efficacy was observed at 12 mg once weekly: -24.2% body weight at 48 weeks in the obesity trial [1]. These are study-design facts from published protocols — not dosing recommendations. Retatrutide is not approved, and what dose would be prescribed, if approval occurs, has not been determined.
How to mix retatrutide with bacteriostatic water?
No mixing protocol for retatrutide exists outside clinical trials. In Phase 2/3 trials, retatrutide was supplied as a pre-formulated, sterile solution — not as lyophilized powder requiring reconstitution. Research-labeled material outside trials lacks any validated protocol. Providing a mixing guide here would misrepresent the state of published science and the compound's unapproved status. This site does not provide preparation instructions for gray-market materials.
Is retatrutide a GLP-3?
No — and the term is a misnomer. There is no GLP-3 receptor. Retatrutide is a GIP/GLP-1/glucagon triple agonist (also called a triagonist or tri-agonist). The "GLP-3" label appears in popular media and community discussions but has no pharmacological basis. Retatrutide is the third major incretin-class candidate after GLP-1 agonists and dual GIP/GLP-1 agonists — that chronological sequence likely drives the misnaming [3][9].
Is retatrutide available?
Through clinical trials only. Retatrutide is not commercially available and not approved by any regulator as of mid-2026 [9]. Research-labeled material sold outside trials is unregulated and of unverified identity and purity. The FDA issued warning letters to gray-market retatrutide vendors in 2025 citing Federal FD&C Act violations.
What is retatrutide used for?
In clinical trials, retatrutide has been studied for: obesity (48-week Phase 2 RCT, Phase 3 TRIUMPH program); type 2 diabetes (36-week Phase 2 RCT); MASLD / metabolic fatty liver disease (Phase 2a substudy); cardiovascular outcomes (dedicated outcomes RCT); and chronic kidney disease (TRANSCEND-CKD Phase 3 trial [10]). No indication is approved. A 2025 review characterized retatrutide's multi-outcome potential across metabolic disease as a compound with the highest weight-loss efficacy seen in the incretin class to date [6].
What receptors does retatrutide target?
Three receptors: GLP-1R (glucagon-like peptide-1 receptor), GIPR (glucose-dependent insulinotropic polypeptide receptor), and GCGR (glucagon receptor). All three are class-B G protein-coupled receptors signaling through the cAMP/PKA pathway. Cryo-EM structural studies confirmed simultaneous engagement at all three, at near-atomic resolution (2.68/3.26/2.84 Å) [3]. Relative potency vs endogenous hormones: ~8.9× at GIPR, ~0.4× at GLP-1R, ~0.3× at GCGR.
Is retatrutide legal?
In the US, retatrutide is not scheduled as a controlled substance, but it is an unapproved new drug under the Federal Food, Drug, and Cosmetic Act. Possessing or administering unapproved new drugs outside a clinical trial is legally ambiguous and may violate FD&C Act provisions. The FDA has issued warning letters to companies selling retatrutide outside clinical trials. Regulatory status varies by country; consult applicable jurisdiction. This site summarizes the published literature and does not provide legal advice.
How often do you take retatrutide?
In all published trials, retatrutide was administered by subcutaneous injection once weekly. The once-weekly schedule is supported by the compound's approximately 6-day half-life, established in Phase 1b pharmacokinetic studies [4]. This is a study-design observation from published protocols — not a prescription or recommendation.
What is the half-life of retatrutide?
Approximately 6 days in humans, established in the Phase 1b first-in-human study [4]. This half-life — nearly a full week — supports once-weekly subcutaneous dosing. It is engineered through a C20 fatty-diacid acyl chain that reversibly binds to serum albumin, slowing renal clearance and extending the compound's time in circulation compared to shorter-acting peptides.